首页 | 本学科首页   官方微博 | 高级检索  
     


Feasibility of 2–deoxy–2–[18F]fluoro–D–glucose– A85380–PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo
Authors:Dr. med. Jan Bucerius  Alexius Y. Joe  Jörn Schmaljohann  Daniela Gündisch  Martina Minnerop  Hans-Jürgen Biersack  Ullrich Wüllner  Michael J. Reinhardt
Affiliation:(1) University of Bonn, Department of Nuclear Medicine, Sigmund-Freud-Str. 25, 53105 Bonn, Germany;(2) University of Bonn, Department of Pharmaceutical Chemistry, Kreuzbergweg 26, 53115 Bonn, Germany;(3) University of Bonn, Department of Neurology, Sigmund-Freud-Str. 25, 53105 Bonn, Germany
Abstract:Summary  Nicotinic acetylcholine receptors mediate the parasympathetic autonomic control of cardiac function. Aim of this study was the assessment of cardiac nicotinic acetylcholine receptor distribution with a novel (α4β2) nicotinic acetylcholine receptor PET ligand (2–deoxy–2– [18F]fluoro–D–glucose–A85380) in humans. Five healthy volunteers without cardiac disease and six patients with either Parkinson's disease or multiple system atrophy without additional overt cardiac disease were evaluated with 2–deoxy–2–[18F]fluoro–D–glucose–A85380 PET–imaging to assess the cardiac parasympathetic innervation and the putative impact of both disorders. 2–deoxy–2– [18F]fluoro–D–glucose–A85380 whole body PET–scans were performed on a Siemens PET/CT biographTM 75.4 min±6.7 after i.v. injection of 371.2±58.1 MBq. Average count rate density of left ventricle ROI's and a standard ROI in the right lung were measured within three consecutive slices of 10.0 mm thickness. Heart–to–lung ratios were calculated in each volunteer and patient. Tracer uptake in the left ventricle could be measured in all of the five volunteers and the six patients. Heart–to–lung ratios in the volunteer group were not different from patients suffering from Parkinson's disease or MSA (3.2 ± 0.5 vs 3.2 ± 0.8 and 2.96±0.7, mean ± SD), respectively. Human cardiac nicotinic acetylcholine receptors can be visualized and measured by 2–deoxy–2– [18F]fluoro–D–glucose–A85380 PET scans both in cardiac–healthy subjects and patients suffering from Parkinson's disease or multiple system atrophy. The heart– as well as the lung–tracer uptake was almost constant throughout all subjects leading to a good target–to–background ratio. These first results suggest no impact of either PD or MSA on cardiac nicotinic acetylcholine receptors. The Article “Feasibility of 2-deoxy-2-[18F]fluoro-D-glucose-A85380-PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo” by J. Bucerius et al. (the online version can be found at has been published in issue 95 (2006):105–109. Unfortunately a wrong notation for the tracer was given. Instead of 2-deoxy-2-[18F]fluoro-D-glucose-A85380 it should be 2-[18F]-A85380. The publisher apologies for any inconvenience caused by this mistake.
Keywords:Nicotinic acetylcholine receptors  human heart  positron emission tomography  Parkinson’  s disease  multiple system atrophy
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号